Growth Hormone Therapy Stocks List

Recent Signals

Date Stock Signal Type
2021-05-11 ASND Crossed Above 20 DMA Bullish
2021-05-11 ASND MACD Bearish Signal Line Cross Bearish
2021-05-11 ASND Bullish Engulfing Bullish
2021-05-11 LUMO Lower Bollinger Band Walk Weakness
2021-05-11 LUMO NR7 Range Contraction
2021-05-11 NVO Upper Bollinger Band Walk Strength
2021-05-11 NVO New 52 Week Closing High Bullish
2021-05-11 NVO New 52 Week High Strength
2021-05-11 NVO Pocket Pivot Bullish Swing Setup

Recent News for Growth Hormone Therapy Stocks

Date Stock Title
May 11 ASND Ascendis Pharma's TransCon PTH Provides Durable Benefit, Is Well Tolerated Even After One Year Treatment In Hypoparathyroidism
May 10 ASND Ascendis Pharma A/S Announces Preliminary 58-Week Results from Open-Label Extension of Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism Demonstrated Durable Benefit and a Well-Tolerated Safety Profile
May 7 NVO Trading in Novo Nordisk shares by board members, executives and associated persons on 7 May 2021
May 7 NVO Novo Nordisk A/S purchases B shares worth DKK 2,586 million from Novo Holdings A/S under the 2021 share repurchase programme
May 7 NVO PFE vs. NVO: Which Stock Should Value Investors Buy Now?
May 6 ASND Ascendis Pharma A/S Announces Presentations for TransCon™ PTH at Upcoming Medical Conferences
May 6 ASND Should You Consider Investing in Ascendis Pharma (ASND)?
May 6 NVO These Top 2 Healthcare Companies Are in a Race to Riches
May 6 LUMO Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q1 2021 Results - Earnings Call Transcript
May 6 NVO Novo Nordisk A/S (NVO) CEO Lars Jorgensen on Q1 2021 Results - Earnings Call Transcript
May 5 NVO Novo Nordisk A/S (NVO) Q1 2021 Earnings Call Transcript
May 5 LUMO Lumos Pharma EPS misses by $0.17
May 5 LUMO Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
May 5 NVO Novo Nordisk A/S 2021 Q1 - Results - Earnings Call Presentation
May 5 NVO Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
May 5 NVO Novo Nordisk boosts 2021 sales, profit growth outlook
May 5 NVO Novo Nordisk rise 3% on Q1 results; 2021 outlook raised
May 5 NVO Novo Nordisk's Q1 Sales Buoyed By GLP-1 Products, Lifts FY21 Guidance
May 5 NVO Novo Nordisk reports Q1 results
Related Industries: Biotechnology